The AstraZeneca vaccine should only be given to people over the age of 30 years decided by the National Vaccination Committee. Following the press conference of the European Medicines Agency and the admission of an EMA executive that the AstraZeneca vaccine is associated with thrombosis but its benefits are much greater, the National Vaccination Committee met to decide what will apply in our country. Nouns, that is,, this means that the vaccination program continues normally in our country.
The announcement of the National Vaccination Committee for the AstraZeneca vaccine
THE National Vaccination Committee closely monitors current data (communications from international organizations and regulators, Scientific Publications) about the thromboembolic events that have occurred in people who have been vaccinated with vaccine of AstraZeneca.
What is known to date
According to recent reports, Very rare cases of thrombosis have been reported with thrombocytopenia following vaccination against COVID-19. It usually is thrombosis venous sinuses of the brain or other rare localities in combination with thrombocytopenia and, sometimes, bleeding. These cases have been reported as immunologically prone thrombocytopenia after vaccination (Vaccine-Induced ProthromboticImmune Thrombocytopenia, VIPIT) and the pathophysiological mechanism of their induction is considered to be analogous to thrombocytopenia after heparin administration (Heparin InducedThrombocytopenia, HT). There is no, so far, documented association of these events with a previous history of thrombosis, thrombocytopenia or hereditary thrombophilia. also, There is currently no evidence of an association with other predisposing factors and this rare condition appears to be a temperamental reaction to first exposure to the AZ vaccine..
The majority of people who have been reported internationally with these events so far are women under the age of 60 years and symptoms appear up to two weeks after vaccination. However, Cases have also been reported in men and people of a wider range of ages, while the distribution of age and sex in all vaccinated patients is still to be clarified, in order to better interpret the existing data.Therefore, There is currently considerable uncertainty in estimating the incidence of this very rare adverse event in different age groups., but there is a tendency for a small increase in frequency at younger ages. On the contrary, The risk of serious COVID-19 disease has been documented to increase significantly with age, with younger adults having the lowest risk.
THE European Medicines Agency (EMA) in a recent announcement (7/4/2021) and after taking into account all available data so far, κατέληξε στο συμπέρασμα ότι οι εκδηλώσεις θρόμβωσης σε συνδυασμό με θρομβοπενία αποτελούν πολύ σπάνιες ενδεχόμενες ανεπιθύμητες ενέργειες του εμβολίου AZ. particularly, to Coreper have been reported, from the countries of the European Economic Area (EEA) and the United Kingdom, 169 cases of thrombosis of the venous sinuses of the brain and 53 visceral thrombosis with thrombocytopenia in total 34.000.000 doses of the AZ vaccine.
Until today, There are no reports of very rare thrombocytopenia after vaccination with the second dose of AZ vaccine.
Summarizing the international data so far, the frequency of thrombotic manifestations with thrombocytopenia estimated at 1 to 150.000 doses of the AZ vaccine Mrthe frequency of corresponding deaths in 1,5 to 1.000.000 doses. The outcome of these cases is expected to improve with early identification and treatment. In contrary, the chance of dying from COVID-19 disease itself is overwhelmingly higher: in our country, according to the data of EODY to 31/12/2020, the death rate is 23 as 35 per 1.000.000 population in individuals 30-39 years, 46 as 94 per 1.000.000 population in individuals 40-49 years, and much older as you get older (see Annex table). Επισημαίνεται ότι η νόσος COVID-19 αυξάνει 30 as 80 times the risk of thrombosis of the venous sinuses of the brain.
In GREECE, since the beginning of the pandemic have been confirmed more than 288.230 cases of SARS-CoV-2 infections and 8.680 deaths. As part of the national vaccination campaign, have been vaccinated to date more than 1.352.770 citizens with at least one vaccine dose and more than 705.000 with two doses of vaccine. Until 8/4/2021, have been granted 1.530.168 Pfizer / BioNTech vaccine doses, 148.178 Moderna vaccine doses and 378.997 doses vaccine of AstraZeneca. So far, A case of large vessel thrombosis and thrombocytopenia following AZ vaccination has been reported to the AEO., which has been identified as possibly related to vaccination and which has been included in the initial case assessment by Coreper.
in conclusion, the risk of serious illness and death from COVID-19 is overwhelmingly higher than the risk of thrombocytopenia after vaccination, especially at ages older than 30 years. The National Vaccination Committee, after evaluating the available data, recommends continuing the vaccination program with any available vaccine, including the AstraZeneca vaccine, in the elderly 30 years and older.